Last reviewed · How we verify
NCT02320357: CLOPUS
Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous
Phase 1, PHASE2 trial testing Treatment by clopidogrel in Systemic Lupus Erythematous in 18 participants. Completed in 11 September 2017.
11 September 2017
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 19 August 2015 |
| Primary completion | 11 September 2017 |
| Estimated completion | 11 September 2017 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Treatment by clopidogrel — full drug profile →
Conditions studied
- Systemic Lupus Erythematous — all drugs for Systemic Lupus Erythematous →
Sponsor
University Hospital, Bordeaux
Who can join
18 and older, any sex, with Systemic Lupus Erythematous. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
CD40 Ligand (CD40L) has been identified as a key feature in systemic lupus erythematosus (SLE) pathogenesis, a systemic autoimmune disease characterized by a multiorgan involvement. As platelets are a major source of soluble CD40L (sCD40L), we propose to study the effect of clopidogrel, a platelet inhibitor, on plasmatic sCD40L levels in SLE patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Interferon Interrupted: Are P2Y<sub>12</sub> Antagonists the Next Step to Target Platelets in Autoimmunity?
Roweth HG. · · 2024 · PMID 39444935 · DOI 10.1016/j.jacbts.2024.06.011
Verify or expand the search:
- PubMed search for NCT02320357
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Lupus Erythematous
Currently open trials in the same condition.
- NCT06339957 — Rheumatology Diet Study · recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02320357 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 25 October 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02320357.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing